Physician profile
Patrick J Mcmanus
NPI 1558360735
$649.37
in general payments reported to CMS, 2019-2025
14 companies · $48.61 in 2025
The $48.61 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $45.50 · 2021: $39.72 · 2022: $49.97 · 2023: $295 · 2024: $50.12 · 2025: $48.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $224.41 | 2023 | Kyphon Express II Kyphopak Tray |
| Novo Nordisk INC | $104.75 | 2019-2023 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.06 | 2020-2022 | |
| Pfizer INC. | $46.80 | 2021-2024 | |
| Abbott Laboratories | $38.17 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $35.72 | 2019-2023 | Veozah |
| Boston Scientific Corporation | $29.96 | 2024 | Watchman Access System |
| Mayne Pharma Commercial LLC | $26.25 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.91 | 2020 | |
| Lilly USA, LLC | $17.67 | 2023 | Mounjaro |
| Mylan Specialty L.P. | $16.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.06 | 2019 | |
| Amgen INC. | $13.81 | 2023 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.